Evaluation of the Typical Spinal Block During Cesarean Delivery
Launched by OREGON HEALTH AND SCIENCE UNIVERSITY · Jan 4, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Primary Objective:
1. Evaluate the accuracy of sensory testing with blunt plastic 16-gauge cannula during the 15 minutes after spinal injection for predicting spinal failure. Cephalad sensory dermatomal levels will be assessed at 1 (t1), 3 (t3), 5 (t5), 7 (t7), 9 (t9), 11 (t11), 13 (t13), and 15 (t15) minutes after intrathecal 1.6 ml 0.75% bupivacaine in 8.25% dextrose combined with 15 mcg fentanyl and 150 mcg morphine (study solution). Spinal failure, which is defined as inability to achieve a T4 level to pinprick by the 15-minute timepoint or intraoperative pain (VAS \> 0) requiring trea...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing cesarean delivery under spinal or combined spinal epidural anesthesia
- • BMI between 20 and 40 kg/m2
- • Height between 5 feet 2 inches and 5 feet 10 inches.
- • English and non-English speaking patients, if interpretive services are available
- Exclusion Criteria:
- • Patient refusal
- • Contraindications to neuraxial anesthesia (coagulopathy, CNS pathology, infection at site of needle puncture)
- • Allergy to any study medications
- • Use of epidural anesthesia
- • Emergency (red) cesarean delivery
- • Conditions that impact dermatomal sensory testing including spinal cord injury with sensory deficits and abdominoplasty
- • Prison inmates
- • Decisionally impaired individuals
- • Pregnancies involving multiple fetuses
About Oregon Health And Science University
Oregon Health and Science University (OHSU) is a leading academic medical center dedicated to advancing health through research, education, and patient care. As a prominent sponsor of clinical trials, OHSU leverages its extensive expertise in various medical fields to facilitate innovative research aimed at improving patient outcomes. The institution is committed to ethical standards and rigorous scientific methodologies, fostering collaborations that enhance the development of new therapies and interventions. With a focus on translating research discoveries into clinical practice, OHSU plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Portland, Oregon, United States
Patients applied
Trial Officials
Brandon M Togioka, MD
Principal Investigator
Oregon Health and Science University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported